SUS ENVIRONMENT at COP30: Co-building a Brighter Tomorrow with Waste-to-Energy
SHANGHAI, Nov. 20, 2025 /PRNewswire/ -- From November 10 to 21, 2025, the 30th United Nations Climate Change Conference (COP 30) was held in Belem, Brazil. Over 50,000 delegates from more than 190 countries and regions attended, jointly advancing...
Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its...
MindHYVE's ChironAI™ Showcased at Peshawar Institute of Cardiology's CME on Cardiovascular Imaging Innovation"
PESHAWAR, Pakistan, Nov. 18, 2025 /PRNewswire/ -- The Peshawar Institute of Cardiology – Medical Teaching Institute (PIC-MTI) hosted a high-profile Radiology Continuing Medical Education (CME) session on "Innovations in Cardiovascular Imaging,"...
Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research
DURHAM, N.C. and SEOUL, South Korea, Nov. 17, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a...
WKBC 2025: CLEARCHANG Highlights Korean Engineering Excellence in Air Purifier and Indoor Air Purification Systems
In Atlanta, CLEARCHANG's window-mounted air purifier demonstrated the synergy of design, ventilation, and sustainable indoor air purification. SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- CLEARCHANG Co., Ltd., a pioneer in advanced air purifier...
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved...
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
CHENGDU, China, Nov. 10, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA),...
Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress
Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. The non-inferiority...
Singapore's Sharpa Wins CES 2026 Innovation Award for Groundbreak AI Robotic Hand SharpaWave
SINGAPORE, Nov. 7, 2025 /PRNewswire/ -- Sharpa, a Singapore-based AI robotics company, announced that its flagship product, the dexterous robotic hand SharpaWave, has been named a CES 2026 Innovation Awards Honoree in the Robotics category....
ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut
SUZHOU, China, Nov. 7, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key...